Get the Stockscreener App
0.5468
1.05%
0.0057
BiomX Inc stock is traded at $0.5468, with a volume of 478.83K.
It is up +1.05% in the last 24 hours and up +26.78% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$0.5411
Open:
$0.5429
24h Volume:
478.83K
Relative Volume:
0.11
Market Cap:
$14.51M
Revenue:
-
Net Income/Loss:
$-26.56M
P/E Ratio:
-0.8412
EPS:
-0.65
Net Cash Flow:
$-22.29M
1W Performance:
-2.01%
1M Performance:
+26.78%
6M Performance:
-42.97%
1Y Performance:
-59.68%
1-Day Range:
$0.52
$0.56
1-Week Range:
$0.4732
$0.56
52-Week Range:
$0.34
$1.6196
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.5468 | 13.66M | 0 | -26.56M | -22.29M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
Published on: 2025-08-20 04:33:53 - classian.co.kr
BiomX announces U.S. FDA placed clinical hold on Phase 2b trial of BX004 - TipRanks
BiomX’s mid-stage cystic fibrosis trial put on clinical hold; Santen makes a deal with RemeGen - Endpoints News
Correction to BiomX Article - MarketScreener
BiomX Faces FDA Hold on Phase 2b Study - TipRanks
BiomX's BX004: A Phage Therapy Revolution in the Orphan Drug Market - AInvest
BiomX Inc. Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis - MarketScreener
BiomX Inc. Reports Q2 2025 Progress and Financials - MSN
Technical Models Suggest BiomX Inc. May Rebound SoonJuly 2025 Breakouts & High Accuracy Swing Entry Alerts - thegnnews.com
Does BiomX Inc. fit your quant trading modelQuarterly Profit Summary & Weekly Watchlist of Top Performers - Newser
Applying chart zones and confluence areas to BiomX Inc.Recession Risk & Scalable Portfolio Growth Ideas - Newser
What institutional flow reveals about BiomX Inc.July 2025 Fed Impact & Growth Focused Entry Point Reports - Newser
Should you wait for a breakout in BiomX Inc.2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - Newser
Applying big data sentiment scoring on BiomX Inc.2025 Trading Recap & Verified Swing Trading Watchlists - Newser
Earnings visualization tools for BiomX Inc.2025 Bull vs Bear & Growth Focused Entry Point Reports - Newser
What Fibonacci levels say about BiomX Inc. reboundPortfolio Growth Summary & Long-Term Investment Growth Plans - Newser
BiomX Inc. Stock Performance After Earnings: Historical InsightsJuly 2025 Macro Moves & Free Technical Pattern Based Buy Signals - Newser
Can trapped investors hope for a rebound in BiomX Inc.July 2025 Sector Moves & Stock Portfolio Risk Management - Newser
BiomX Inc. stock prediction for this weekShare Buyback & Step-by-Step Trade Execution Guides - Newser
How BiomX Inc. stock performs during market volatilityTrade Analysis Summary & AI Enhanced Market Trend Forecasts - Newser
Analyzing drawdowns of BiomX Inc. with statistical toolsShort Setup & Accurate Technical Buy Alerts - Newser
BiomX Inc. (AMEX:PHGE) Q2 2025 Earnings Call Transcript - Insider Monkey
BiomX Inc. shares fall 2.82% premarket after reporting second quarter 2025 financial results. - AInvest
BiomX outlines BX004 Phase IIb results expected in Q1 2026 as BX211 advances toward registrational study - MSN
BiomX Posts Q2 Loss With 14% Cost Drop - AOL.com
BiomX's Q2 2025 Earnings Call: Unraveling Contradictions in BX211 and BX004 Development Strategies - AInvest
Trend analysis for BiomX Inc. this weekJuly 2025 Sector Moves & Short-Term High Return Ideas - Newser
BiomX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Transcript : BiomX Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
BiomX Inc (PHGE) Reports Q2 2025 EPS of -$0.33, Net Loss of $6 M - GuruFocus
BiomX Reports Q2 GAAP EPS of -$0.19, Cash Balance Decreases to $15.2 Million - AInvest
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates - TradingView
News impact scoring models applied to BiomX Inc.July 2025 News Drivers & Weekly Chart Analysis and Trade Guides - Newser
Technical Models Suggest BiomX Inc. May Rebound Soon [July 2025 Breakouts]Risk Managed Investment Entry Signals - 선데이타임즈
BiomX Announces Q2 2025 Financial Results and Initiates Phase 2B Trial for Cystic Fibrosis Treatment - AInvest
BiomX: Positioning Phage Therapy as a High-Probability, High-Impact Play in the Antibiotic Resistance Crisis - AInvest
How to escape a deep drawdown in BiomX Inc.Market Volume Summary & Reliable Momentum Entry Alerts - Newser
BiomX Earnings Preview: What to Expect on August 13th - AInvest
BiomX Inc.’s Price Action Aligns with Quant SignalsBreakout Confirmation With Entry Tracker Enabled - 선데이타임즈
What to Expect From BiomX's Earnings - 富途牛牛
Should I buy BiomX Inc. stock before earningsPredictive Analytics for Equity Growth Potential - Newser
Can BiomX Inc. hit a new high this monthIntraday Price Action Forecast Planner - Newser
Why BiomX Inc. is moving todayTrend Analysis for Safer Market Entries - Newser
BiomX (PHGE) Projected to Post Earnings on Wednesday - Defense World
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):